The Department of Health and Human Services will establish a public-private consortium to increase U.S. production of essential medicines and active pharmaceutical ingredients, the White House announced today. The consortium will initially focus on 50-100 critical drugs from the Food and Drug Administration’s essential medicines list, and commit an initial $60 million to develop novel technologies to manufacture active ingredients domestically.   
 
President Biden in February directed federal agencies to review and recommend actions to address vulnerabilities in the supply chains for active pharmaceutical ingredients, essential minerals, semiconductors and large capacity batteries. The HHS actions are among the recommendations included in a new White House report based on those reviews, which also address supply vulnerabilities in those other sectors.

 

Related News Articles

Headline
The Food and Drug Administration July 22 released an early alert for Novum IQ large volume infusion pumps by Baxter. The company stated that the pump has…
Headline
Senior leaders from the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, along with White House…
Headline
President Trump July 7 issued an executive order, “Extending the Modification of the Reciprocal Tariff Rates,” which extends the original July 9 reciprocal…
Headline
The AHA submitted a statement today to the House Energy and Commerce Subcommittee on Health for a hearing today on the health care supply chain. The AHA…
Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response June 5 announced it selected two locations to test an…
Headline
The U.S. Court of International Trade May 28 blocked a series of tariffs issued by the Trump administration under the International Emergency Economic Powers…